Literature DB >> 34199002

Targeting Canonical and Non-Canonical STAT Signaling Pathways in Renal Diseases.

Lili Gai1, Yuting Zhu1, Chun Zhang1, Xianfang Meng2.   

Abstract

Signal transducer and activator of transcription (STAT) plays an essential role in the inflammatory reaction and immune response of numerous renal diseases. STATs can transmit the signals of cytokines, chemokines, and growth factors from the cell membrane to the nucleus. In the canonical STAT signaling pathways, upon binding with their cognate receptors, cytokines lead to a caspase of Janus kinases (JAKs) and STATs tyrosine phosphorylation and activation. Besides receptor-associated tyrosine kinases JAKs, receptors with intrinsic tyrosine kinase activities, G-protein coupled receptors, and non-receptor tyrosine kinases can also activate STATs through tyrosine phosphorylation or, alternatively, other post-translational modifications. Activated STATs translocate into the nucleus and mediate the transcription of specific genes, thus mediating the progression of various renal diseases. Non-canonical STAT pathways consist of preassembled receptor complexes, preformed STAT dimers, unphosphorylated STATs (U-STATs), and non-canonical functions including mitochondria modulation, microtubule regulation and heterochromatin stabilization. Most studies targeting STAT signaling pathways have focused on canonical pathways, but research extending into non-canonical STAT pathways would provide novel strategies for treating renal diseases. In this review, we will introduce both canonical and non-canonical STAT pathways and their roles in a variety of renal diseases.

Entities:  

Keywords:  STAT; renal diseases; signal transduction

Year:  2021        PMID: 34199002     DOI: 10.3390/cells10071610

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  150 in total

Review 1.  Structure, function, and regulation of STAT proteins.

Authors:  Cheh Peng Lim; Xinmin Cao
Journal:  Mol Biosyst       Date:  2006-09-26

Review 2.  Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2015-02-03       Impact factor: 7.658

Review 3.  Regulation of cytokine signaling pathways by PIAS proteins.

Authors:  Ke Shuai
Journal:  Cell Res       Date:  2006-02       Impact factor: 25.617

4.  IL-22 ameliorates renal ischemia-reperfusion injury by targeting proximal tubule epithelium.

Authors:  Ming-Jiang Xu; Dechun Feng; Hua Wang; Youfei Guan; Xiaoqiang Yan; Bin Gao
Journal:  J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 10.121

Review 5.  Regulation of STAT signaling by acetylation.

Authors:  Shougang Zhuang
Journal:  Cell Signal       Date:  2013-05-22       Impact factor: 4.315

Review 6.  Update on Lupus Nephritis.

Authors:  Salem Almaani; Alexa Meara; Brad H Rovin
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

7.  Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin.

Authors:  Dominic Chi Hiung Ng; Bao Hong Lin; Cheh Peng Lim; Guochang Huang; Tong Zhang; Valeria Poli; Xinmin Cao
Journal:  J Cell Biol       Date:  2006-01-09       Impact factor: 10.539

8.  Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.

Authors:  Chulwon Kim; Sang Hyun Baek; Jae-Young Um; Bum Sang Shim; Kwang Seok Ahn
Journal:  BMC Nephrol       Date:  2016-02-25       Impact factor: 2.388

Review 9.  Unilateral Ureteral Obstruction as a Model to Investigate Fibrosis-Attenuating Treatments.

Authors:  Elena Martínez-Klimova; Omar Emiliano Aparicio-Trejo; Edilia Tapia; José Pedraza-Chaverri
Journal:  Biomolecules       Date:  2019-04-08

10.  A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion.

Authors:  Wei Huang; Zizheng Dong; Fang Wang; Hui Peng; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  ACS Chem Biol       Date:  2014-03-24       Impact factor: 5.100

View more
  2 in total

1.  Drug Repurposing in Rare Diseases: An Integrative Study of Drug Screening and Transcriptomic Analysis in Nephropathic Cystinosis.

Authors:  Francesco Bellomo; Ester De Leo; Anna Taranta; Laura Giaquinto; Gianna Di Giovamberardino; Sandro Montefusco; Laura Rita Rega; Anna Pastore; Diego Luis Medina; Diego Di Bernardo; Maria Antonietta De Matteis; Francesco Emma
Journal:  Int J Mol Sci       Date:  2021-11-27       Impact factor: 5.923

Review 2.  Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases.

Authors:  Min-Ji Kim; Jae-Han Jeon
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.